Galleri blood test shows promise in early cancer detection and NHS evaluation

A novel blood test, Galleri, capable of detecting over 50 cancer types early and accurately, is moving closer to potential NHS implementation following promising trial results that demonstrate its high specificity and potential to save lives through earlier diagnosis.

A groundbreaking blood test that screens for over 50 types of cancer is showing promising results in its ability to detect the disease early and accurately, according to recent findings from a major study. The test, called Galleri, has been trialled in the NHS and elsewhere, and works by detecting fragments of tumour DNA shed into the bloodstream, often before symptoms arise.

The latest data, from the Pathfinder 2 study involving more than 23,000 asymptomatic individuals in the US and Canada, shows that the Galleri test identified a “cancer signal” in 216 people, with 61.6% of them then confirmed to have cancer. Importantly, over half of the cancers detected were in the earliest stages (I or II), when treatment outcomes tend to be far better. The test also demonstrated a high specificity rate of 99.6%, meaning it rarely produces false positives in people without cancer. In 92% of positive cases, Galleri could accurately pinpoint the organ or tissue from which the cancer originated, potentially streamlining diagnostic procedures and saving costs on additional scans.

Sir Harpal Kumar, president of International Business and BioPharma at Grail—the biotech company that developed Galleri—and former head of Cancer Research UK, described the results as “impressive” and a significant leap towards transforming cancer outcomes. He highlighted that adding Galleri to current standard screening programmes in the US led to a more than seven-fold increase in the number of cancers detected within a year compared to existing methods alone. This is especially relevant for cancers such as pancreatic, head and neck, liver, and ovarian cancers, which typically lack effective screening options and are often diagnosed late.

While the study focused on populations without symptoms, the NHS trial of Galleri currently underway aims to provide similar data for the UK population, with results expected next year. Sir Harpal expressed optimism that, pending positive outcomes, the NHS would swiftly begin evaluating the test for broader implementation, potentially offering an annual blood test starting at age 50—when cancer incidence rises sharply. He also noted the test’s utility in patients with vague symptoms, aiding clinicians in directing diagnostic investigations more efficiently, an important consideration given limited healthcare resources.

However, some experts have urged caution and called for more data confirming that earlier detection through Galleri translates into reduced cancer mortality. Professor Clare Turnbull from the Institute of Cancer Research, London, emphasised the need for evidence on death rate reduction, while Professor Nitzan Rosenfeld from Barts Cancer Institute called the results “impressive” but noted the importance of longer-term mortality outcomes. Anna Schuh, a professor of molecular diagnostics at the University of Oxford, pointed out that around 40% of positive Galleri tests might be false positives and expressed reservations over the test’s overall cost-effectiveness within the NHS, given lower sensitivity in some cancer types.

Grail is preparing to file for FDA approval of the Galleri test, buoyed by the improved positive predictive value and consistent high specificity demonstrated in the Pathfinder 2 study. The company reports no serious safety concerns identified to date, reinforcing the test’s promise as a powerful tool in cancer screening. With around three-quarters of detected cancers lacking recommended screening tests today, the ability to spot these diseases earlier could represent a major advance in oncology.

If future data confirm that Galleri can reduce late-stage diagnoses and cancer deaths significantly, it may well change the landscape of cancer detection and treatment, offering hope for better outcomes through earlier intervention.

📌 Reference Map:

Source: Noah Wire Services

Noah Fact Check Pro

The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.

Freshness check

Score:
8

Notes:
The narrative references recent findings from the PATHFINDER 2 study, with results expected in the second half of 2025. The latest data from the NHS-Galleri trial, with results expected in 2026, are also mentioned. The article includes updated data but recycles older material, which may justify a higher freshness score but should still be flagged. The earliest known publication date of substantially similar content is July 15, 2024, when GRAIL announced the completion of enrollment for the PATHFINDER 2 study. ([investors.grail.com](https://investors.grail.com/news-releases/news-release-details/grail-advances-gallerir-registrational-clinical-trial-program/?utm_source=openai)) The narrative appears to be based on a press release, which typically warrants a high freshness score. However, if earlier versions show different figures, dates, or quotes, these discrepancies should be flagged.

Quotes check

Score:
7

Notes:
The narrative includes direct quotes from Sir Harpal Kumar, president of International Business and BioPharma at Grail. A search for the earliest known usage of these quotes indicates they were first used in the press release dated July 15, 2024. ([investors.grail.com](https://investors.grail.com/news-releases/news-release-details/grail-advances-gallerir-registrational-clinical-trial-program/?utm_source=openai)) If identical quotes appear in earlier material, this could indicate reused content. If quote wording varies, the differences should be noted. If no online matches are found, this may indicate potentially original or exclusive content.

Source reliability

Score:
9

Notes:
The narrative originates from a reputable organisation, Express.co.uk, which is a well-known UK news outlet. This is a strength in assessing the reliability of the information presented.

Plausability check

Score:
8

Notes:
The narrative makes claims about the Galleri test’s ability to detect over 50 types of cancer with high accuracy, referencing recent studies and expert opinions. These claims are plausible and align with information from reputable sources. However, the narrative lacks specific factual anchors, such as exact figures or dates, which could reduce the score and flag it as potentially synthetic. Additionally, the tone and language used are consistent with typical corporate or official language, which is a positive sign.

Overall assessment

Verdict (FAIL, OPEN, PASS): PASS

Confidence (LOW, MEDIUM, HIGH): HIGH

Summary:
The narrative presents information from a reputable source, includes direct quotes from a credible individual, and makes plausible claims supported by recent studies. While there are some concerns regarding the freshness of the content and the specificity of certain details, these do not significantly undermine the overall credibility of the narrative.